How to delay dementia? New screening test, drug may help
==========
On World Alzheimer’s Day, the importance of timely diagnosis for early dementia is highlighted; Alzheimer’s Disease International (ADI) surveyed 40,000 people in 166 countries about dementia testing; Hamid Sohrabi developed the McCusker Subjective Cognitive Impairment Inventory (McSCI-S) screening test for dementia risk, currently being released in China; the test assesses cognitive changes over two years; timely diagnosis can provide support and treatment options; donanemab, approved by the FDA in June 2024, slows cognitive decline by 35% over 18 months; donanemab and lecanemab are disease-modifying drugs targeting amyloid plaques; donanemab is administered every four weeks, while lecanemab is every two weeks; concerns exist regarding drug availability and cost, with donanemab exceeding £20,000 annually in the UK; critics argue about the high production costs and potential side effects; the societal cost of dementia was over $1.3 trillion in 2019.
#Dementia #Alzheimer's #Screening #Treatment #Health #Research #Drugs #Diagnosis #ClinicalTrials #PublicHealth
https://www.scmp.com/lifestyle/health-wellness/article/3279147/can-you-delay-alzheimers-how-new-dementia-screening-test-and-drug-may-help
South China Morning Post /
npub1x2…knuvq
2024-09-21 06:00:15
Author Public Key
npub1x2q0x7w5tqx0x3j9tdvkvqmetarpr8axhpjq7qw5xxrcysdwtrzssknuvqSeen on
wss://relay.damus.ioPublished at
2024-09-21 06:00:15Event JSON
{
"id": "3a1c4f6a92b4678c1ccfa4b70c7f6eb0a130a4207fb15a9ed003f187515de349",
"pubkey": "3280f379d4580cf346455b596603795f46119fa6b8640f01d431878241ae58c5",
"created_at": 1726891215,
"kind": 1,
"tags": [],
"content": "How to delay dementia? New screening test, drug may help\n==========\n\nOn World Alzheimer’s Day, the importance of timely diagnosis for early dementia is highlighted; Alzheimer’s Disease International (ADI) surveyed 40,000 people in 166 countries about dementia testing; Hamid Sohrabi developed the McCusker Subjective Cognitive Impairment Inventory (McSCI-S) screening test for dementia risk, currently being released in China; the test assesses cognitive changes over two years; timely diagnosis can provide support and treatment options; donanemab, approved by the FDA in June 2024, slows cognitive decline by 35% over 18 months; donanemab and lecanemab are disease-modifying drugs targeting amyloid plaques; donanemab is administered every four weeks, while lecanemab is every two weeks; concerns exist regarding drug availability and cost, with donanemab exceeding £20,000 annually in the UK; critics argue about the high production costs and potential side effects; the societal cost of dementia was over $1.3 trillion in 2019.\n\n#Dementia #Alzheimer's #Screening #Treatment #Health #Research #Drugs #Diagnosis #ClinicalTrials #PublicHealth\n\nhttps://www.scmp.com/lifestyle/health-wellness/article/3279147/can-you-delay-alzheimers-how-new-dementia-screening-test-and-drug-may-help",
"sig": "5767063fdd66baf1484ec5a3e6def7916b4a5ea394518cdd8bb4e2aea5755421e0512f0644b615705751e0efd2c214b64111660055f5a1c1794cf6c62d49ea9b"
}